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Non-alcoholic fatty liver disease (NAFLD) is a clinico-
pathological syndrome characterized by lipid deposition
in hepatocytes, in the absence of excessive alcohol con-
sumption. It is now considered part of metabolic syn-
drome, with insulin resistance as a primary underlying
derangement. It is widely accepted that a ﬁrst hit leads
to hepatic steatosis, and further hits to necro-inﬂamma-
tion and ﬁbrosis (steatohepatitis), with oxidative stress,
reactive oxygen species (ROS) and endoplasmatic reticu-
lum stress playing a major role [1]. Mitochondrial dys-
function seems to be crucial in the pathogenesis of
NAFLD, with less fatty acid oxidation favoring fat accu-
mulation [2], and also being themajor source ofROS con-
tributing to necro-inﬂammation [3–5]. In fact, NAFLD
has been considered a mitochondrial disease [6,7].
2. Uncoupling proteins
Uncoupling proteins (UCPs) are mitochondrial
inner-membrane proteins, whose main function is to
mediate proton leak across the inner membrane and to
uncouple substrate oxidation from ATP synthesis [8].
The liver is the largest metabolic organ in the human
body, and mitochondrial proton leak accounts for 20–
30% of the oxygen consumption of isolated resting hepa-0168-8278/$36.00  2009 European Association for the Study of the Liver.
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is plausible that they might participate in hepatic mito-
chondrial proton leak and certain deregulated metabolic
pathways. There are several UCP homologues, UCP1
expressed in brown adipose tissue, UCP3 expressed in
brown adipose tissue and skeletal muscle and UCP4
and 5 expressed in the brain [10]. UCP2 is rather ubiq-
uitous, however in the liver it has been mostly localized
to Kupﬀer cells, with very low or undetectable levels in
hepatocytes [11]. Nonetheless, UCP2 expression was
detected in healthy and diseased hepatocytes in human
percutaneous liver biopsy specimens [12]. The fact that
UCP2 expression in normal hepatocytes is so unusually
low remains perplexing, raising the possibility of the
existence of other proteins involved in hepatocyte pro-
ton conductance. In fact, a novel liver-speciﬁc uncou-
pling protein was isolated in 2004, termed HDMCP
(hepatocellular carcinoma down-regulated mitochon-
drial carrier protein), that exhibits reduced expression
in hepatocellular carcinoma and shows evolutionary
conservation between humans, mice, and rats [13]. In
this issue of the Journal, Jin et al. report new and excit-
ing data about the potential role of this new uncoupling
protein in NAFLD [14].
3. Uncoupling proteins and NAFLD
UCPs may provide a beneﬁcial mechanism that per-
mits an adaptation to increased fatty acid supply,
enhancing fatty acids (FA) oxidation and thus confer-
ring a theoretical beneﬁt in preventing hepatic steatosis.
In fact, there are several mechanisms (Fig. 1), through
which the up-regulation of uncoupling proteins, can
alleviate hepatic steatosis and the ensuing lipotoxicityPublished by Elsevier B.V. All rights reserved.
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Fig. 1. Proposed UCP related mechanisms. NADH/FADH2 reduced during fatty acids oxidation, function as electron donors to the phosphorylative
respiration which leads to the oxygen dependent production of ATP. The electron transport chain has four enzyme complexes in the inner mitochondrial
membrane, the last being cytochrome c oxidase which gives two electrons to one O2 molecule and in combination with 2H+, converts it to H2O. That
electron transport is coupled to a movement of protons (H+) from the mitochondrial matrix to the intermembrane space producing an electrochemical
gradient. When energy is needed, H+ reenter the mitochondrial matrix, and the energy produced by that H+ movement is used by ATP synthase to
convert ADP in ATP. However, mitochondrial hyperpolarization increases half life of mobile electron carriers, allowing incomplete electron transport and
partial reduction of O2 molecules, with the production of oxygen reactive species such as O2. Uncoupling proteins (UCPs) are mitochondrial inner-
membrane proteins that mediate H+ leak across the inner membrane and uncouple substrate oxidation from ATP synthesis. UCPs enhance fatty acids
oxidation through enhancing recycling of oxidised NAD+/FAD+; allowing entrance of CoASH (rate-limiting coenzyme to beta oxidation and Krebs
cycle) through a cycle of fatty acids inﬂow of acyl-CoA, cleavage of CoASH and outﬂow of fatty acids. Also, removal of fatty acids from mitochondria
and lipid peroxide anions, protects further mitochondrial injury (adapted from McLellan et al. [15]). [This ﬁgure appears in colour on the web.]
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allow increased beta-oxidation of FA in the mitochon-
dria, supporting ongoing fatty acid oxidation as
opposed to accumulation, through reoxidation of
NADH to NAD+; (2) it may provide a translocation
mechanism that prevents accumulation of non-esteriﬁed
fatty acids (NEFA) and their harmful eﬀects in the mito-
chondrial matrix; (3) mediate free fatty acid (FFA) out-
ﬂow from the mitochondrial matrix, allowing re-entry as
acyl-CoA, functioning as CoASH donor necessary for
beta-oxidation [15]; (4) activate AMPK (AMP-activated
protein kinase) expression [16,17], that powerfully steers
metabolic pathways from energy accumulation to
energy expenditure and fuel preference from glucose to
fatty acids [18]. AMPK promotes fatty acid oxidation
and ketogenesis, and inhibits peripheral lipolysis and
lipogenesis [18]. Interestingly, it was found that in
UCP2 knockout mice, fasting initially promotes periph-
eral lipolysis and hepatic fat accumulation at less than
expected rates, but culminates in protracted steatosis,
indicating diminished hepatic utilization and clearance
of FAs [19].
Concerning NAFLD, an increased hepatic expression
of UCP2 in animal models was found [20], as well as atrend for increased expression in the liver biopsies from
non-alcoholic steatohepatitis (NASH) patients [21]. A
large number of studies on various tissues conﬁrmed
that UCP2 expression is generally increased in response
to elevated plasma FA levels [20,22,23]. In vitro expo-
sure of primary cultured rat hepatocytes to lipids
resulted in up-regulation of UCP2, indicating that excess
UCP2 may indeed originate in hepatocytes as opposed
to non-parenchymal liver cells [24]. However, until
now, a protective eﬀect of UCPs in the prevention of
hepatic steatosis has not been demonstrated. In fact,
Baﬀy et al. found no diﬀerence in the degree of steatosis
in ob/ob mice knockout for UCP2 and ob/ob wild-type
mice [23].
A possible role of UCPs in the second hit of NAFLD
is also appealing. UCPs may unleash the ﬂow of elec-
trons in the respiratory chain, thereby preventing the
over-reduction of respiratory complexes and excessive
mitochondrial ROS formation [25], protecting the cell
from lipoperoxidation and diminishing necro-inﬂamma-
tion. Furthermore, UCPs can protect the mitochondria
from lipid peroxides formed by the reaction of FA and
ROS, either through a decrease in ROS production or
through a direct ﬂip ﬂop of those lipid peroxides across
H. Cortez-Pinto, M.V. Machado / Journal of Hepatology 50 (2009) 857–860 859the mitochondrial membrane [17]. However, in animal
models of NAFLD, oxidative stress and ROS produc-
tion persists, despite an increase in UCP2 [4]. It may
be speculated that even increased amounts of UCP2
are not suﬃcient to control the exacerbated intracellular
ROS generation in fatty liver. Also, the increased
expression of UCPs, may compromise ATP synthesis,
increasing the vulnerability to energy depletion [26].
That might explain the increased susceptibly to ische-
mia–reperfusion [20], that is markedly reduced in
UCP2 knockouts [27], and to Fas-mediated liver injury
[28] in fatty liver. When translating these data to a
potential eﬀect in NASH, once again, Baﬀy et al. did
not ﬁnd any diﬀerence in steatohepatitis and ﬁbrosis
score in ob/ob mice, knockout for UCP2, and wild-type
ob/ob mice [23].
In a report from Jin et al. in this issue it is suggested
that the novel uncoupling protein, HDMCP may have a
protective eﬀect concerning steatosis development. In a
series of elegant studies, the authors ﬁrst conﬁrmed that
HDMCP had an uncoupling eﬀect on yeast mitochon-
drial respiration, being more concentrated in the mito-
chondria. Next, using sequence analysis, they
demonstrated the similarity between UCPs and
HDMCP sequences. Furthermore, and more relevant
for the issue in discussion, a signiﬁcantly increased
expression of HDMCP was seen in a high-fat rat
NAFLD model. Sequentially, by in vitro exposition of
hepatocytes to a mixture of oleic and palmitic acid
(HFFA), a time dependent increase in the levels of
HDMCP was observed in the steatotic hepatocytes;
when the expression of HDMCP was partially silenced
by HDMCP-ShRNA, steatosis was aggravated. Simul-
taneously, ATP levels of NAFLD livers and steatotic
hepatocytes were signiﬁcantly decreased, the latter neg-
atively correlating with HDMCP protein levels; this
ATP reduction was partially antagonized by silencing
HDMCP. Interestingly, the incubation of hepatocytes
with HFFA resulted in diminished H2O2 production,
that was to some extent reversed when HDMCP was
partially knocked out [14]. Accordingly, the authors
claim the potential beneﬁts of the adaptive eﬀect of
HDMCP in protecting hepatocytes from steatosis, con-
sidering it as an attractive drug target for therapeutic
purposes [14]. However, one should question why did
this uncoupling protein have an eﬀect on the degree of
steatosis, when UCP2 modulation did not inﬂuence
the severity of fatty liver disease [23]. One potential
explanation was recently proposed by Baﬀy [17]. In con-
trast with normal liver, where the expression of UCP2
dominates in Kupﬀer cells while it is rather limited in
hepatocytes [11], this pattern appears to be the opposite
in fatty liver, where there is an increased hepatocellular
UCP2 expression. Conversely, a down-regulation of
UCP2 in macrophages and increased ROS production
has been shown in obese mice, a change that presumablyextrapolates to Kupﬀer cells [29]. This cell-speciﬁc up-
regulation of UCP2 can also partially explain the
absence of perceivable diﬀerences in obesity related fatty
liver of mice with and without UCP2 [23]. If the regula-
tion of HDMCP is not cell-speciﬁc, its up-regulation
might have a much more profound eﬀect.
On the other hand, when considering the potential
beneﬁts of uncoupling agents, such as HDMCP, on
NAFLD that should be tempered by the recognition
of their potential to increase the risk of necrosis. The
fact that Jin et al. reported a signiﬁcant negative corre-
lation between HDMCP and ATP implies an increased
risk for necrosis when HDMCP is increased. In fact,
establishing a parallel with the UCP2, in two studies
in obese mice, the down-regulation of UCP2, either
related with metformin treatment [30] or with, probio-
tics [31] was associated with an increased recovery of
hepatocyte ATP stores and an improvement in necro-
inﬂammation. These observations suggest that the eﬀect
of uncoupling proteins may be deleterious, potentially
leading to an increased risk of necro-inﬂammation/ste-
atohepatitis. In fact, as acknowledged by the authors,
there is the possibility that HDMCP may have an eﬀect
in preventing steatosis, although simultaneously increas-
ing the risk for NASH [14].
Conversely, studies have shown that uncoupling pro-
teins tend to protect from apoptosis [32,33], probably
through a reduction of ROS production [34]. This could
be beneﬁcial, since apoptosis is a signiﬁcant pathological
feature of steatohepatitis [21,35]. However, it has been
suggested that the persistent activation of UCP2, by
reducing apoptosis, might contribute to the increased risk
of hepatocellular carcinoma observed in NAFLD [17].
Even so, the eﬀect ofHDMCPon apoptosis and its poten-
tial consequences on carcinogenesis is still unknown.
In conclusion, the possibility of modulating
mitochondrial respiration and the fate of excessive fatty
acids with this novel uncoupling protein is very interest-
ing and promising. It should however be regarded with
caution, since these are interacting mechanisms with
unpredictable eﬀects.
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